I-Mab Starts Phase Ib Trial of Re-purposed RA Treatment for COVID-19

Suzhou I-Mab will start the second part of its China Phase I trial of TJM2 in patients with cytokine release syndrome (CRS) associated with severe COVID-19. TJM2, developed by I-Mab to treat rheumatoid arthritis, is a neutralizing antibody for human granulocyte-macrophage colony stimulating factor (GM-CSF), which plays a critical role in tissue inflammation. After completing a safety review, the trial's data monitoring committee recommended the continuation of the double-blind study at the higher 6 mg/kg dose level that will enroll 144 patients. More details.... Stock Symbol: (NSDQ: IMAB) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.